Moderna shares surged 6% amid a broader market rotation from AI and tech stocks into healthcare, outperforming peers BioNTech and Pfizer. This rally is supported by positive clinical data from August showing Moderna's personalized mRNA cancer vaccine improved outcomes in a late-stage melanoma trial when combined with Merck's Keytruda. The healthcare sector's defensive appeal and this promising trial result are driving investor interest. The next key factor will be the release of fuller trial data to confirm these early positive results and sustain the rally.
Moderna leads healthcare gains on Pluang, trading at USD 238.35 with a 5.32% rise as of Oct 16, 2026 00:12 WIB, reflecting strong investor demand with 83% buy orders. BioNTech and Pfizer also see modest increases, up 1.92% and 1.69% respectively, with Pfizer attracting the highest buy interest at 88%. This trading activity highlights the ongoing rotation into healthcare stocks noted in the news.
